In another burst of news from the Drug Information Association conference this week, Octagon Research Solutions announced a way to connect output from data collection into the regulatory submission process. The firm’s electronic data capture (EDC) system and its process and document management solution are the foundation for a boundary-bursting approach to R&D processes using electronic data. Kirk Gallion, president of Octagon Research Solutions, noted: “The concept of ‘on-demand’ generation of templated content can also be applied to other areas of the submission process, where meta-data, content and templates can be automatically merged to create newly aggregated and consistently formatted content.”

TrialStat Corporation, an electronic data capture provider, added Innovaderm Research, a Canadian clinical research organization (CRO) specializing in dermatology, to the list of CROs in its alliance program. The firm’s CRO channel program provides discounts on EDC services in exchange for specific cross-promotional actions. “We selected TrialStat’s CA 4.0 [EDC system] because of its ability to facilitate data collection, data monitoring, and data management in a CRF 21 Part 11 environment,” said Robert Bissonnette, president and founder, Innovaderm. Here’s the release.

Phase Forward, a provider of electronic data capture and drug safety, announced an alliance with AG Mednet, an imaging network. The firms will now connect Phase Forward’s InForm integrated trial management (ITM) system and AG Mednet’s imaging transport network. The integrated offering will enable clinical trial images to be tracked and managed within the InForm system. The solution will help streamline the process of transporting images between clinical sites and central reviewers, and will enable trial sponsors to access the status of patient images. “Clinical trial sponsors need a way to transport patient images more quickly and efficiently for less cost, and a real-time capability to track and manage these images,” said Martin Young, VP, corporate development and marketing and Phase Forward.

Chiltern International announced that it has entered into a global partnership agreement with EPS International, a provider of clinical development services in Asia. Chiltern will provide services to EPS International from its network of offices in 23 countries throughout Europe, North America, South America and India. For its part, EPS will provide clinical development services for the Asian region from its offices in Japan, China, Singapore, Korea and Taiwan. Said Glenn Kerkhof, CEO of Chiltern: “Asia is becoming an increasingly attractive market for clinical trial services and finding a partner with a meaningful presence and experience of conducting clinical trials throughout Southeast Asia is an important development for Chiltern. With EPS as our partner in this region we continue to focus on our mission to deliver expert, high quality clinical development services around the world,” Kerkhof said.

Frontage Laboratories, a provider of bioanalytical, pre-clinical and drug development services to the pharmaceutical industry, announced it has acquired Advanced Biomedical Research (ABR), a full service CRO. The new firm will have formulation development, bioanalytical and GMP testing services, a state-of-the-art 72-bed clinical research facility, and “turn key” multinational Phase II-IV CRO services. “Years of partnering with Frontage have already proven the synergies of our combined resources and capabilities,” commented Michael Willett, president and CEO of ABR.

TranSenda International announced the launch of Office-Smart Clinical Trial Manager, a clinical trial management system (CTMS) that can draw on documents and data inside Microsoft Office. “We’re proud to offer next-generation clinical trial management solutions that are optimized to take advantage of Microsoft’s Office system,” said Robert Webber, president and CEO of TranSenda. “The best prospects for progress start with the basics of improving office productivity and focusing our solutions on the business process side of conducting clinical trials.” 

Have a news release? Send it to .(JavaScript must be enabled to view this email address).

d9A2t49mkex